In addition, we reveal the clinical significance of higher TRIM21 expression in NPC patients and provide proof-of-concept evidence that targeting TRIM21 with genetic tools may enhance the antitumour efficacy of radiotherapy. This evidence concerns the gene TRIM21 and nasopharyngeal carcinoma.